Ucb Pharma, S.a.

Ucb Biopharma Sprl

Ucbbiopharma Srl

Celltech R&d Limited

Celltech Therapeutics Limited

Ucb Biophara Sprl

David Paul Humphreys

Sam Philip Heywood

Mark Ellis

Emma Dave

Ralph Adams

Pallavi Bhatta

Shirley Jane Peters

Laura Griffin

Daniel John Lightwood

Philip Jonathan Bassett

James Heads

Pareshkumar Manjibhai Patel

Kerry Louise Tyson

Alastair David Griffiths Lawson

Terence Seward Baker

Martyn Kim Robinson

Bryan John Smith

David Edward Ormonde Knight

Diane Marshall

Andrew Paul Chapman

Karine Jeannine Madeleine Hervé

Mariangela Spitali

Robert Anthony Griffin

Paul Edward Stephens

Joanne Elizabeth Compson

Andrew Charles Payne

Matthew Jon Timothy Page

Nicola Louise Fisher

Brendon Mackenzie

Matthew Cox

Farnaz Fallah-Arani

Terry Seward Baker

Karine Jeannine Madeleine HervÉ

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of a) a polypeptide chain of formula (I): VH—CH—X—V; and b) a polypeptide chain of formula (II): VL-CL-Y—Vand pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.

Multispecific antibody constructs

The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a C1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the C1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.

Antibodies of the class IGG4

The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab' fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

Dual specificity antibody fusions

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)Vx-Cx-X-V; and b) a polypeptide chain of formula (II): (Vyy)Vy-Cc) a polypeptide of formula (III):Vwherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, Vrepresents a variable domain,independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between Vand V, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

Single linker FabFv antibodies and methods of producing same

The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.

Multimeric Fc proteins

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH&#x2014;CH&#x2014;X&#x2014;V; and b) a polypeptide chain of formula (II): VL-CL-Y&#x2014;Vand pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.

The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti FcRn antibodies and proteins made by the methods described herein.

Recombinant bacterial host cell for protein expression

The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Antibody molecules which bind TNF alpha

The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.

Sequence symmetric modified IgG4 bispecific antibodies

The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, Vand the heavy chain region, Vof the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.

Disulfide stabilised antibodies and fragments thereof

This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.

Neutralising antibodies to the major exotoxins TCDA and TCDB of

The present disclosure provides a binding protein comprising: a polypeptide heavy chain comprising: VH-(X)n-VH&#x2014;CH (X)y wherein VHis a first variable domain, VHis a second variable domain, CH is a constant domain, Xrepresents an amino acid or peptide, Xrepresents an Fc region, n is 0 or 1 and y is independently 1 or 2, and a polypeptide light chain comprising: VL-(X)n-VL-C wherein VL1 is a first variable domain, VLis a second variable domain, C is a constant domain, Xrepresents an amino acid or peptide and n is 0 or 1, wherein the heavy chain and light chain are aligned such that VHand VLform a first binding domain, and VHand VLform a second binding domain and wherein: there is a disulfide bond between VHand VL, and/or there is a disulfide bond between VHand VL, and use thereof in treatment.

Disulfide stabilized DVD-Ig molecules

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)Vx-Cx-X-V; and b) a polypeptide chain of formula (II): (Vyy)Vy-Cy c) a polypeptide of formula (III): Vwherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, Vrepresents a variable domain,independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.

Growing community of inventors

Slough, United Kingdom

David Paul Humphreys